AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2018
Nov 29, 2018
35334_dirs_2018-11-29_103e4457-e3b3-45ba-9d73-29826d09af65.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-11-27
Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-27 | Common Stock | A | 2500 | — | Acquired | 778307 | Direct |
Footnotes
F1: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019.
More from AIM ImmunoTech Inc.
Share Issue/Capital Change
2026
Jun 11
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15